| scholarly article | Q13442814 |
| P2093 | author name string | Zack JA | |
| Brooks DG | |||
| Kitchen SG | |||
| Scripture-Adams DD | |||
| Kitchen CM | |||
| P2860 | cites work | A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children | Q24620746 |
| Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy | Q28253761 | ||
| HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure | Q28283258 | ||
| Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection | Q29547852 | ||
| Viral dynamics in human immunodeficiency virus type 1 infection | Q29547908 | ||
| Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy | Q29615992 | ||
| Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy | Q29615993 | ||
| Recovery of replication-competent HIV despite prolonged suppression of plasma viremia | Q29615995 | ||
| Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection | Q29619738 | ||
| Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection | Q36225040 | ||
| Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse | Q36362448 | ||
| Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1 | Q36362732 | ||
| Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes | Q36368207 | ||
| Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle | Q36693174 | ||
| Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines | Q36851755 | ||
| In vivo pathogenesis of a human immunodeficiency virus type 1 reporter virus | Q39100446 | ||
| Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. | Q39592932 | ||
| Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes | Q39595263 | ||
| The SCID-hu mouse as a model for HIV-1 infection | Q41546977 | ||
| Detection of cell cycle subcompartments by flow cytometric estimation of DNA-RNA content in combination with dual-color immunofluorescence | Q41720055 | ||
| HIV induces thymus depletion in vivo | Q45305157 | ||
| Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection | Q45854138 | ||
| Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy | Q47960975 | ||
| In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. | Q52050894 | ||
| Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy | Q57075703 | ||
| Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells | Q57075707 | ||
| Frequent infection of peripheral blood CD8-positive T-lymphocytes with HIV-1. Edinburgh Heterosexual Transmission Study Group | Q71472914 | ||
| Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy | Q73308229 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 459-464 | |
| P577 | publication date | 2001-04-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Generation of HIV latency during thymopoiesis | |
| P478 | volume | 7 |
| Q36601933 | A Simple Mouse Model for the Study of Human Immunodeficiency Virus |
| Q73704191 | A new latent HIV reservoir |
| Q28477926 | A stochastic model of latently infected cell reactivation and viral blip generation in treated HIV patients |
| Q33849878 | Activated peripheral CD8 lymphocytes express CD4 in vivo and are targets for infection by human immunodeficiency virus type 1. |
| Q28477657 | Activation of latent HIV using drug-loaded nanoparticles |
| Q37336473 | An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate |
| Q26767476 | Animal Models for HIV Cure Research |
| Q37041160 | Animal models to achieve an HIV cure |
| Q90594756 | Barriers for HIV Cure: The Latent Reservoir |
| Q91607012 | Benefits and limitations of humanized mice in HIV persistence studies |
| Q34514930 | CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection |
| Q30435358 | CXCR4 acts as a costimulator during thymic beta-selection |
| Q38945956 | CXCR4 tropic human immunodeficiency virus type 1 induces an apoptotic cascade in immature infected thymocytes that resembles thymocyte negative selection |
| Q38078562 | Cellular and molecular mechanisms involved in the establishment of HIV-1 latency |
| Q35233845 | Cocaine reduces thymic endocrine function: another mechanism for accelerated HIV disease progression |
| Q34132738 | Combination of biological screening in a cellular model of viral latency and virtual screening identifies novel compounds that reactivate HIV-1 |
| Q37645582 | Curing HIV: Pharmacologic approaches to target HIV-1 latency |
| Q38973362 | Current views on HIV-1 latency, persistence, and cure. |
| Q39895237 | Determinants of the establishment of human immunodeficiency virus type 1 latency |
| Q37419972 | Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency |
| Q36132255 | Developmental regulation of P-glycoprotein activity within thymocytes results in increased anti-HIV protease inhibitor activity |
| Q34362915 | Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency |
| Q35777137 | Disruption of Type I Interferon Induction by HIV Infection of T Cells |
| Q37460585 | Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques |
| Q42563241 | E box motifs as mediators of proviral latency of human retroviruses. |
| Q39682575 | Effect of latent human immunodeficiency virus infection on cell surface phenotype |
| Q39753161 | Effects of prostratin on T-cell activation and human immunodeficiency virus latency |
| Q35857603 | Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner |
| Q54942553 | Epigenetic Modulation of CD8⁺ T Cell Function in Lentivirus Infections: A Review. |
| Q39933477 | Epigenetic silencing of human immunodeficiency virus (HIV) transcription by formation of restrictive chromatin structures at the viral long terminal repeat drives the progressive entry of HIV into latency |
| Q39783316 | Establishment and maintenance of HIV latency: model systems and opportunities for intervention |
| Q39712159 | Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction |
| Q33223350 | Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. |
| Q36708954 | Experimental approaches to the study of HIV-1 latency |
| Q34567084 | Finding a cure for HIV: will it ever be achievable? |
| Q38101294 | From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication |
| Q56778321 | Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART |
| Q34564279 | Genetically modified immunocompetent cells in HIV infection. |
| Q35867173 | HIV RNA suppression and immune restoration: can we do better? |
| Q74095853 | HIV latency in naive T cells |
| Q40321405 | HIV latency in the humanized BLT mouse |
| Q38270498 | HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes |
| Q33774665 | HIV persistence: chemokines and their signalling pathways. |
| Q36746403 | HIV reservoirs and latency models. |
| Q35557244 | HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites |
| Q37502488 | HIV type-1 latency: targeted induction of proviral reservoirs |
| Q37607912 | HIV-1 regulation of latency in the monocyte-macrophage lineage and in CD4+ T lymphocytes |
| Q35716711 | HIV-1 replication and pathogenesis in the human thymus |
| Q34876018 | HIV-1 reservoirs |
| Q33513977 | HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. |
| Q36976156 | HIV-1 transcription and latency: an update |
| Q37021788 | HIV/AIDS eradication |
| Q34960856 | Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence |
| Q37492762 | High levels of human immunodeficiency virus infection of CD8 lymphocytes expressing CD4 in vivo. |
| Q36330062 | Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication |
| Q36773289 | Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo |
| Q35160655 | Human immunodeficiency virus persistence and production in T-cell development |
| Q42929742 | Human immunodeficiency virus reactivation by phorbol esters or T-cell receptor ligation requires both PKCalpha and PKCtheta |
| Q34124009 | Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli |
| Q39459609 | Humanized Mouse Models for Human Immunodeficiency Virus Infection. |
| Q38838864 | Humanized mice for HIV and AIDS research |
| Q37089865 | Humanized mouse models of HIV infection |
| Q36690000 | Identification of T cell-signaling pathways that stimulate latent HIV in primary cells |
| Q36944005 | Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes |
| Q39315707 | In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies |
| Q41932886 | In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication. |
| Q36515119 | In vivo platforms for analysis of HIV persistence and eradication |
| Q37039142 | Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells |
| Q33849629 | Induction of TAK (cyclin T1/P-TEFb) in purified resting CD4(+) T lymphocytes by combination of cytokines |
| Q36958820 | Induction of simian AIDS in infant rhesus macaques infected with CCR5- or CXCR4-utilizing simian-human immunodeficiency viruses is associated with distinct lesions of the thymus |
| Q42734211 | Influence of host gene transcription level and orientation on HIV-1 latency in a primary-cell model |
| Q31115718 | Inhibition of Tat-mediated transactivation and HIV-1 replication by human anti-hCyclinT1 intrabodies |
| Q45735559 | Interleukin-7 and infection itself by human immunodeficiency virus 1 favor virus persistence in mature CD4(+)CD8(-)CD3(+) thymocytes through sustained induction of Bcl-2. |
| Q39685564 | Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype |
| Q35044157 | Latency in human immunodeficiency virus type 1 infection: no easy answers |
| Q35665924 | Latent HIV-1 infection of resting CD4⁺ T cells in the humanized Rag2⁻/⁻ γc⁻/⁻ mouse |
| Q35761152 | Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity |
| Q33579827 | Low and undetectable breast milk interleukin-7 concentrations are associated with reduced risk of postnatal HIV transmission |
| Q33510903 | Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy |
| Q34263657 | Molecular Characterization, Reactivation, and Depletion of Latent HIV |
| Q40470185 | Mouse serum factor(s) down-modulate the CD4 and CXCR4 molecules on human T cells conferring resistance to HIV infection in NOG mice. |
| Q34569382 | Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy |
| Q34941973 | Pharmaceutical approaches to eradication of persistent HIV infection |
| Q30834495 | Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies |
| Q42093067 | Primary cell model for activation-inducible human immunodeficiency virus |
| Q41918740 | Quiescence promotes latent HIV infection and resistance to reactivation from latency with histone deacetylase inhibitors |
| Q40329064 | Rapid expression of human immunodeficiency virus following activation of latently infected cells |
| Q34416398 | Rational development of prophylactic HIV vaccines based on structural and regulatory proteins |
| Q63246353 | Recent Updates on Mouse Models for Human Immunodeficiency, Influenza, and Dengue Viral Infections |
| Q27013114 | Recent developments in human immunodeficiency virus-1 latency research |
| Q36887625 | Regulation of HIV-1 latency by T-cell activation. |
| Q40673293 | Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication |
| Q34857454 | Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy |
| Q42849831 | Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages |
| Q33508788 | Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation |
| Q37802560 | Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells |
| Q26849806 | Studies of retroviral infection in humanized mice |
| Q33845503 | Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages |
| Q35543827 | T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis |
| Q34960413 | Targeting HIV: antiretroviral therapy and development of drug resistance. |
| Q39110897 | Targeting type I interferon-mediated activation restores immune function in chronic HIV infection |
| Q39545359 | The Application of Humanized Mouse Models for the Study of Human Exclusive Viruses. |
| Q34544409 | The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit |
| Q35001008 | The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection |
| Q36099451 | Therapeutic role of CD8+ T cells in HIV-1 infection: targets and suppressors of viral replication |
| Q35115656 | Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes. |
| Q30833740 | Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system |
| Q37615893 | Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs |
| Q28077662 | Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research |
| Q39963401 | Viral complementation allows HIV-1 replication without integration |
Search more.